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Background:  An important aspect of successful heart transplantation (HTx) is appropriate donor selection. With a relatively stable organ 
supply in the face of rising organ demands, donor selection remains a critical yet poorly standardized aspect. The aim of this study was to 
determine whether elevated donor serum cardiac troponin I (cTnI) is associated with adverse events after HTx.
methods:  Between January 1999 and August 2013, cTnI serum concentration was measured in samples collected from 161 consecutive 
donor hearts. The cTnI levels were normal in 116 donors (72.0%) and elevated in 45 donors (28%). Each study subject was classified as 
having elevated cTnI if any level exceeded 0.3 ng/mL.
results:  The estimated left ventricular ejection fraction on the initial donor echocardiogram was similar in both groups (67%±14% vs. 
63%±12%; p=0.09). Donors with elevated cTnI levels did not require higher doses of inotropic drugs before transplantation and had similar 
hemodynamic profiles compared with donors with normal cTnI levels. The mean allograft cold ischemic times also were similar between the 
groups (211±44min vs. 199±53min; p=0.14). Postoperatively, recipients of grafts from donors with elevated cTnI levels had a significantly 
higher incidence of postoperative acute kidney injury, longer ventilation time, and intensive care unit stay. Furthermore, 30-day mortality 
(22.2% vs. 8.6%; p=0.03) and 1-year mortality (46.7% vs. 17.2%; p=0.0002) were significantly higher in recipients of donor hearts with 
elevated cTnI levels.
conclusion:  Elevated cTnI serum concentration in donors is an independent prognostic marker for adverse events after HTx. Utilizing it as 
additional parameter may improve heart donor selection.
